We are currently offering medical products in four Therapeutic Areas:
(You can click on the logos to find out more on the selected Therapeutic Areas)
In this area Emerging Pharma markets products for common gastrointestinal diseases such as acute diarrhoea, gastroenteritis, constipation, haemorrhoids, and for the pre-surgery cleansing of the colon.
Neurological disorders affect patients of various ages. Emerging Pharma’s pharmaceutical products that fall under this category are used in the treatment of cerebral palsy, post-stroke, and dementia.
Our products in the area of women’s health include antibiotics for cystitis, and media for in vitro fertilisation. Emerging Pharma has an established rapport with obstetricians and gynaecologists.
Diabetic patients require various types of medication at different stages of the disease. Emerging Diabetic Care offers innovative products to provide optimal glucose control and prevent progression of diabetic nephropathy for all diabetic patients.
Emerging Pharma also market other products that does not fall into the first four categories.
In sourcing for products worldwide, we maintain a strict policy of representing only one product of its kind at any given time. By not representing competing products, we ensure that we are able to focus exclusively on our chosen principals’ products.
On the other hand, we do actively seek groups of complementary products that can collectively meet the multiple (and related) needs within a therapeutic area.
Emerging Pharma’s core strength is its ability to offer medical professionals a range of complementary products; this convenience increases the likelihood that they will select from our range – all our products then benefit in this way.
This strategy not only gains from being able to leverage existing sales networks and contacts, but also benefits from a brand reinforcement effect, with non-competing products from different principals in the same therapeutic area enhancing one another’s reputation and market performance.
To ensure more concentration of efforts, we currently limit our therapeutic areas to four.
